Renalytix’s use of ground-breaking AI to assess patient biomarker data creates a unique opportunity to identify and save those most likely to progress to CKD. This is potentially life-changing for millions of people and a massive cost-saver for healthcare providers. In the U.S. alone, treatment of CKD accounts for 20% of the Medicare budget or $120 billion per year.
Renalytix faced serious challenges. Trying to integrate their software with the patient systems for each new hospital or healthcare provider was going to take years. Getting clean, validated data into the system was difficult and often relied on manual input from paper-based sources. Also, the initial software builds were monolithic, difficult to change, and each amendment was further slowed by the need to comply with FDA quality controls on ‘medical device’ software.
Renalytix selected us as their partner for accomplishing the company’s life-changing mission.